<DOC>
	<DOCNO>NCT00111878</DOCNO>
	<brief_summary>The primary objective study describe safety tolerability single dose MEDI-534 administer healthy adult volunteer .</brief_summary>
	<brief_title>Study Evaluate MEDI-534 Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Paramyxoviridae Infections</mesh_term>
	<criteria>Male female age 18 40 year ( yet reach 41st birthday ) day randomization Healthy medical history physical examination Available telephone Signed write informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization obtain volunteer Sexually active female , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral , implanted , transdermal contraceptive , intrauterine device ( IUD ) , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) least 30 day prior dose study vaccine , must agree continue use precaution least 30 day dose ; volunteer must also negative serum pregnancy test within 7 day prior dose study vaccine negative urine pregnancy test day study vaccine dose prior administration Sexually active male , unless surgically sterile , must use effective method birth control ( condom abstinence ) must agree continue use precaution least 30 day dose Ability understand comply requirement protocol judged investigator Ability complete followup period 6 month follow dosing require protocol Acute illness day randomization Fever ( great equal 99.5°F oral great equal 100.1°F tympanic ) and/or respiratory illness ( e.g. , cough sore throat ) within 7 day prior randomization Any drug therapy ( chronic ) within 7 day prior randomization ( except certain medication contraceptive , topical [ i.e. , dermatologic ] corticosteroid , infrequent use overthecounter pain reliever , follow approval sponsor ) expect receipt 28 day study vaccine dose Receipt immunoglobulin blood product within 90 day prior screen expect receipt 28 day study vaccine dose Receipt investigational drug within 60 day prior randomization expect receipt study period ( i.e. , 180 day study vaccine dosing ) Receipt approve vaccine within 30 day prior randomization expect receipt 28 day study vaccine dose History immunodeficiency receipt immunosuppressive agent , expect receipt immunosuppressive agent 28 day study vaccine dose Close contact home workplace child 2 year age Household contact immunocompromised ; volunteer also avoid close contact immunocompromised individual least 21 day vaccination History hypersensitivity kanamycin aminoglycoside antibiotic ( gentamicin , tobramycin , etc . ) Previous medical history , evidence , intercurrent chronic illness , opinion investigator , may compromise safety volunteer Any evidence end organ dysfunction Current , history , clinically significant abnormality electrocardiogram ( ECG ) ( screen ECG must within 30 day prior randomization ) Evidence active infection HIV hepatitis A , B , C virus , serologic evidence past infection hepatitis B C virus At screen ( must within 7 day prior randomization ) , follow laboratory test outside laboratory normal range : CBC : hemoglobin ( Hgb ) , WBC count , platelet count ; AST , ALT , BUN , creatinine ; abnormal laboratory value screen panel , opinion principal investigator , may potentially confound analysis study result Nursing mother History alcohol drug abuse past 2 year History medical diagnosis asthma , reactive airway disease , chronic obstructive pulmonary disease ( COPD ) History smoke past 5 year Previous vaccination Respiratory Syncytial Virus ( RSV ) Parainfluenza Virus Type 3 ( PIV3 ) clinical trial Employees research center , individual involve conduct study , family member individual Any condition , opinion investigator , might interfere study vaccine evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Respiratory Syncytial Virus ( RSV ) Parainfluenza Virus Type 3 ( PIV3 )</keyword>
</DOC>